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BACKGROUND AND PURPOSE
We have previously shown that arginase inhibition alleviates hypertension associated with in a diabetic animal model. Here,
we investigated the protective effect of arginase inhibition on hypertension in metabolic syndrome.
EXPERIMENTAL APPROACH
Metabolic syndrome was induced in rats by administration of fructose (10% in drinking water) for 12 weeks to induce
vascular dysfunction. Three arginase inhibitors (citrulline, norvaline and ornithine) were administered daily in the last 6 weeks
of study before and tail BP was recorded in conscious animals. Concentration response curves for phenylephrine (PE), KCl and
ACh in addition to ACh-induced NO generation were obtained in thoracic aorta rings. Serum glucose, insulin, uric acid and
lipid profile were determined as well as reactive oxygen species (ROS) and arginase activity.
KEY RESULTS
Arginase activity was elevated in metabolic syndrome while significantly inhibited by citrulline, norvaline or ornithine
treatment. Metabolic syndrome was associated with elevations in systolic and diastolic BP, while arginase inhibition
significantly reduced elevations in diastolic and systolic BP. Metabolic syndrome increased vasoconstriction responses of aorta
to PE and KCl and decreased vasorelaxation to ACh, while arginase inhibition completely prevented impaired responses to
ACh. In addition, arginase inhibition prevented impaired NO generation and exaggerated ROS formation in metabolic
syndrome. Furthermore, arginase inhibition significantly reduced hyperinsulinaemia and hypertriglyceridaemia without
affecting hyperuricaemia or hypercholesterolaemia associated with metabolic syndrome.
CONCLUSIONS AND IMPLICATIONS
Arginase inhibition alleviates hypertension in metabolic syndrome directly through endothelial-dependent relaxation/NO
signalling protection and indirectly through inhibition of insulin resistance and hypertriglyceridaemia.
Abbreviations
PE, phenylephrine; ROS, reactive oxygen species
Introduction
Using the World Health Organization definition and data
from the National Health and Nutrition Examination Survey,
the age-adjusted prevalence of the metabolic syndrome in the
United States is estimated at 24% and increases to 44% in
adults who are over 60 years (Ford et al., 2002). The metabolic
syndrome is characterized by the variable coexistence of
hyperinsulinaemia, obesity, dyslipidaemia and hypertension.
The pathogenesis of the syndrome has multiple origins.
Obesity and sedentary lifestyle coupled with diet as well as
still largely unknown genetic factors clearly interact to
produce the syndrome (Kolovou et al., 2005). Insulin resist-
ance, which is a hallmark of metabolic disorders, including
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type 2 diabetes mellitus, is also characterized by endothelial
dysfunction (Kim et al., 2006). Insulin, beside its essential
metabolic action, it has also important vascular action which
includes NO production from endothelium leading to
vasodilatation and augmentation of glucose disposal in skel-
etal muscle (Kim et al., 2006). Accordingly, insulin resistance
is at most a modest determinant of hypertension and blood
pressure (Saad et al., 2004).
Reduced availability of L-arginine to endothelial NOS
(eNOS) has been implicated in vascular dysfunction in dia-
betes and a variety of other disease conditions. Arginase,
which metabolizes L-arginine to urea and ornithine, com-
petes directly with NOS for L-arginine. Hence, increases in
arginase activity can decrease tissue and cellular arginine
levels, reducing its availability to eNOS (Romero et al., 2008).
This may lead to decreased NO production and increased
production of superoxide by eNOS (Berkowitz et al., 2003).
Enhanced arginase activity has been implicated in a number
of conditions characterized by vascular dysfunction, includ-
ing diabetic erectile dysfunction (Bivalacqua et al., 2001),
pulmonary hypertension (Morris et al., 2003) and coronary
artery dysfunction (Zhang et al., 2004). During diabetes,
impaired vascular function is closely associated with oxida-
tive stress and vascular inflammation (Romero et al., 2008;
El-Bassossy et al., 2011a), both of which have been associated
with increases in arginase activity and expression (Bivalacqua
et al., 2001). In addition, increased arginase activity has been
reported in diabetic patients and can be reduced by insulin
treatment (Kashyap et al., 2008). Furthermore, arginase inhi-
bition restores in vivo coronary microvascular function in
type 2 diabetic Goto Kakizaki rats (Gronros et al., 2011) and
protects from renal injury in a streptozotocin model of dia-
betes (Morris et al., 2011).
In addition to the production of urea, arginase is also
involved in the biosynthesis of polyamines and the amino
acids, ornithine, proline and glutamate (Cederbaum et al.,
2004). As such, it is not surprising that amino acids such as
ornithine, norvaline and citrulline inhibit arginase (Hunter
and Downs, 1945).
Therefore, the aim of the present work was to examine the
potentially protective effect of the arginase inhibition in the
metabolic syndrome and illustrate the mechanism of this
protective effect.
Materials and methods
Animals
Studies are reported in accordance with the ARRIVE guide-
lines for reporting experiments involving animals (Kilkenny
et al., 2010; McGrath et al., 2010), and carried out in strict
accordance with institutional animal care and use guidelines
consistent with UK standards of care. Seventy-two male
Wistar rats (6 weeks age; Zagazig University, Zagazig, Egypt)
were used in the present study and housed in standard light/
dark cycles with access to standard rat diet ad libitum.
Study protocol
Animals were randomly divided into five experimental
groups (eight animals each): control, metabolic syndrome
(M), citrulline-treated metabolic syndrome (M-citrulline),
norvaline-treated metabolic syndrome (M-norvaline) and
ornithine-treated metabolic syndrome (M-ornithine). In
addition, the effect of arginase inhibitors on control was
studies in three groups: citrulline-treated control, norvaline-
treated control and ornithine-treated control. Metabolic syn-
drome was maintained by giving fructose 10% in drinking
water ad libitum daily for 12 weeks. After 6 weeks, treated rats
were received citrulline (50 mg·kg-1), norvaline (50 mg·kg-1)
and ornithine (200 mg·kg-1) treatment as solution (0.8–1 mL)
in distilled water by orogastric gavage for 6 weeks of study
while control and resistant groups receive water as a vehicle
instead. The doses of citrulline, norvaline and ornithine were
chosen based upon their reported arginase inhibiting activity
(Kang et al., 2000; Romero et al., 2008) and confirmed by
arginase activity measurement.
At the end of the study and 12 h after the last gavage,
blood pressure was measured. Rats were then terminally
anaesthetized with diethyl ether and blood was collected
from the retro-orbital plexus and centrifuged (3000¥ g, 4°C,
20 min) to separate serum that was analysed for glucose, uric
acid, lipid profile and arginase activity. Then, through
opening the abdomen, descending thoracic aorta was care-
fully excised and placed in a Petri dish filled with cold Krebs–
Henseleit buffer containing (in mM): NaCl 118.1, KCl 4.69,
KH2PO4 1.2, NaHCO3 25.0, glucose 11.7, MgSO4 0.5 and CaCl2
2.5. The aorta was cleaned of excess connective tissue and fat
and cut into rings of approximately 3 mm in length. For each
animal, one aortic ring was suspended in an organ bath for
studying vascular reactivity while the second was used to
study ACh-induced NO generation and the third for measur-
ing the reactive oxygen species (ROS) content. In order to
study the acute effect on vascular reactivity, aorta from resist-
ant animals were incubated in organ bath with arginase
inhibitors; citrulline, norvaline or ornithine (all at 1 mM) for
1 h before studying vascular reactivity. These concentrations
and time were chosen based upon those used in previous
reports (Fuentes et al., 1994; Huynh et al., 2009) plus our
preliminary data. In order to investigate the effect of hype-
ruricaemia on vascular reactivity, aortae or kidney isolated
from normal animals were incubated with uric acid (200 mM),
arginase inhibitors or L-arginine for 1 h before studying the
effect on vascular reactivity or arginase activity. The uric acid
incubation concentration was chosen based upon the serum
level of uric acid in animals with metabolic syndrome
observed in our study.
Arginase activity
Arginase activity was measured in serum of chronically
treated animals and in the incubation buffer of isolated aorta
after in vitro treatment by the colorimetric determination of
the arginase enzyme product, urea (Mendez et al., 2002).
Briefly, 100 mL serum or the incubation buffer was incubated
for 1 h with reaction mixture containing the activator (man-
ganese sulphate) and substrate (arginine) in carbonate buffer
(pH 9.5). The produced urea was condensed with diacetyl-
monoxime in an acid medium in the presence of ferric
chloride (oxidant) and carbazide (accelerator). Then, the
absorbance was measured at 525 nm by 6105 UV/Vis
spectrophotometer (Jenway®, Essex, UK). For the in vitro
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experiments, the measured activities were normalized to the
wet weight of the aortic rings.
Serum analysis
Serum glucose was determined colorimetrically using a
Randox reagent kit (Antrim, UK). Triglycerides (TGs) and
total cholesterol were estimated enzymatically using Boe-
hringer Mannheim® colorimetric kit (Mannheim, Germany).
Uric acid was measured colorimetrically by uricase method;
uric acid is converted into hydrogen peroxide, which forms a
red-coloured quinoneimine dye measured at 520 nm. (Fossati
et al., 1980).
Serum insulin level was assayed by sandwich ELISA (Milli-
pore, Cairo, Egypt) that uses microtiter plate coated with
mouse monoclonal anti-rat insulin antibodies. The estimated
insulin resistance index (HOMA-IR) was calculated using the
serum fasting glucose and insulin levels according to the
following equation (Matthews et al., 1985): HOMA-IR =
glucose concentration (mmol·L-1) ¥ insulin (mU·L-1)/22.5.
BP measurement
BP was measured indirectly in a conscious and slightly
restrained rat by the tail cuff method (El-Bassossy et al.,
2012b) using non-invasive blood pressure system attached to
a computerized data acquisition system (ADI Instruments,
Cairo, Egypt). For these measurements, rats were con-
ditioned to the restraint and the warming chamber for
10–20 min·day-1 for at least 3 days before measurements. BP
measurements were performed from 7:00 a.m. to 12:00 p.m.
by the same investigator. After 5–10 min of stabilization in a
warming chamber (35°C), a typical run involved 10 repeti-
tions of the automated inflation–deflation cycle. The mean of
six readings within a 5–10 mmHg range was taken as the BP.
Vascular reactivity
Vascular reactivity was studied using the isolated artery tech-
nique (El-Bassossy et al., 2009). Thoracic aorta rings were
suspended under 8 mN resting tension in individual 30 mL
organ chambers containing Krebs–Henseleit buffer at 37°C
and aerated with 95% oxygen, 5% carbon dioxide. Ring
tension was determined by use of an isometric force trans-
ducer (ADI Instruments, Cairo, Egypt). Force displacement
was recorded with a PowerLab Data Interface Module con-
nected to a PC running Chart software v7 (ADI Instruments).
Rings were equilibrated for 60 min during which time the
bath solution was changed every 30 min. Before beginning
the experiment, vessel viability was assessed by exposing
arteries to KCl (80 mM). This was repeated until stable
responses were achieved (usually two exposures). For study-
ing the vasoconstrictor responsiveness of aorta, cumulative
concentrations of phenylephrine (PE, 10-9 to 10-5M) or KCl
(10 to 100 mM) were added to the organ bath and the
response was recorded. For studying the vasodilator respon-
siveness of aorta, rings were first pre-contracted with sub-
maximal concentrations of PE (3 ¥ 10-7 M in the case of the
diabetic group and 10-6 M in other groups). The submaximal
concentration of PE was chosen to give similar precontrac-
tion in all studied groups. The cumulative concentrations of
acetylcholine (ACh, 10-9 to 10-5 M) were then added to the
organ bath and the response was recorded. At the end of
experiment, aortic rings were removed and weighted. The
recorded responses were normalized to the wet weight of the
used aortic rings.
Microvascular reactivity
In order to support our vascular reactivity findings, part of
the experiments was repeated in a microvascular system
using the isolated perfused kidney. The rat kidney was iso-
lated and perfused as previously described (El-Mas et al.,
2011) with slight modifications. Briefly, rats were killed by
cervical dislocation followed by followed by decapitation, the
abdomen was opened by a midline incision and the left
kidney was exposed. The left renal artery was dissected free
from the surrounding fat. Loose ties were made around the
renal artery. A bevelled 18-gauge needle connected to a 5 mL
syringe filled with heparinized saline (100 U·mL-1) was used
for cannulation. The left renal artery was cannulated via an
incision made in the aorta. The cannula was immediately
secured with ligatures and the kidney was flushed with
heparinized saline and rapidly excised from its surrounding
tissues. The kidney was transferred into a jacketed glass
chamber maintained at 37°C and continuously perfused with
Krebs–Henseleit buffer aerated with 95% oxygen, 5% carbon
dioxide. Kidney perfusion was adjusted at a constant flow rate
of 5 mL·min-1 using a Masterflex® peristaltic pump (Cole-
palmer, Jubail, Saudi Arabia) and the venous effluent was
allowed to drain freely. The kidney perfusion pressure was
continuously monitored by means of a Gould–Statham pres-
sure transducer distal to the pump and recorded using a
PowerLab Data Interface Module connected to a PC running
Chart software v7 (ADI Instruments). As the renal flow was
kept constant, changes in perfusion pressure were indicative
of alterations in renal microvascular resistance. A 30 min
equilibration period was allowed at the beginning of the
experiment to ensure stabilization of the kidney perfusion
pressure. For studying the renal microvascular relaxation,
isolated kidneys were first continuously perfused with PE
(10 mM). After another 30 min equilibration, vasodilatory
responses of the renal vasculature to bolus doses injections of
ACh (0.1, 1, 100, 500 nmol) were established. After washout,
uric acid (200 mM) was added to the perfusion medium for
another 1 h. Then, the renovascular dilatation to ACh was
repeated. After wash out, citrulline was added to the per-
fusion medium for 30 min and the renovascular dilatation to
ACh was investigated.
ACh-induced NO generation
The real-time generation of intracellular NO following ACh
stimulation was investigated with the fluorescence probes
4-amino-5-methylamino-2′,7′-difluorofluorescein diacetate
(DAF-FM) according to the method described by El-Bassossy
et al. (2011b; 2012a). The aorta rings isolated from chroni-
cally treated animals were loaded for 30 min at 37°C with
5 mM of DAF-FM diacetate plus 0.1% Pluronic F-127 in
Krebs–Henseleit buffer containing 25 mM HEPES. Aorta rings
were washed twice and then cut and placed in a chamber
designed especially for fluorescence measurement in aortic
segments with the endothelial side up. 100 mL of Krebs–
Henseleit buffer containing HEPES were added quickly to the
chamber. DAF fluorescence was measured using a LS45 fluo-
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rescence spectrophotometer (PerkinElmer®, Cairo, Egypt)
with remote fibre optic, which allows measurement of tissue
fluorescence in the sample chamber. Readings (lex = 485,
lem = 515 nm) were taken before and every 5 s after ACh
(10-4 M) addition. The NO donor diethyl amine NONOate
(100 nM) was used as a positive control for DAF.
Intracellular of ROS generation
The intracellular levels of ROS were determined by the fluo-
rescent probe dichlorofluorescein diacetate (DCF-DA) accord-
ing to the method described previously by (Ugochukwu and
Cobourne, 2003) with slight modification. Frozen aortae were
homogenized in 20 parts (w/v) of 0.32 M sucrose solution in
ice and the centrifuged at 2000 rpm at 4°C for 15 min. Then,
100 mL of the supernatant was added to 1900 mL 18:1
40 mM·L-1 Tris (pH 7.4): HEPES buffer (10 mM HEPES,
120 mM NaCl, 2.5 mM KCl, 1.2 mM NaH2PO4, 0.1 mM
MgCl2, 5 mM NaHCO3, 6 mM glucose, and 1 mM CaCl2) con-
taining 5 mM DCF-DA plus 0.1% Pluronic F-127. The fluores-
cence was measured (lex = 485, lem = 515 nm) before and
after 2 h of incubation at 37°C. The difference in fluorescence
per hour was used as indicative for ROS formation.
Drugs and chemicals
The following drugs and chemicals were used: STZ, ACh, PE,
SNP, L-Norvaline, L-Ornithine, L-citrulline (Sigma-Aldrich,
Munich, Germany); uric acid (Oxford Laboratory, Mumbai,
India). All the used chemicals were dissolved in double dis-
tilled water.
Statistical analysis
All data are expressed as mean  SEM. Statistical analysis was
performed by ANOVA followed by Newman–Keuls’ post hoc test
using a computer-based curve fitting program (Prism 5,
Graphpad, San Diego, CA, USA). Correlation was calculated
using Pearson’s correlation coefficient.
Results
Arginase activity
Fructose administration (10% in drinking water) was associ-
ated by a significant elevation in serum arginase activity
compared to control (P < 0.001, Figure 1A) while this activa-
tion of arginase enzyme was significantly inhibited by all the
arginase inhibitors used: citrulline, norvaline and ornithine
(P < 0.001, Figure 1A). In vitro incubation of aortae isolated
from normal animals with uric acid (200 mM, 1 h) did not
significantly affected arginase activity. However, incubation
with citrulline (1 mM, 1 h) significantly inhibited arginase
activity in isolated aorta compared with control (P < 0.01,
Figure 1B). On the other hand, incubation with L-arginine
(1 mM, 1 h) led to a significant increase in arginase activity
compared with control (P < 0.05, Figure 1B).
Serum parameters
Fructose administration for 12 weeks led to a significant
elevation in blood glucose and insulin levels and the insulin
resistance index (all at P < 0.001) compared with control
(Table 1). Arginase inhibition by citrulline, norvaline or orni-
thine significantly inhibited the developed hyperglycaemia,
hyperinsulinaemia and insulin resistance associated with
fructose administration (all at P < 0.001, Table 1). Fructose
administration was also associated with hypertriglyceri-
daemia (P < 0.001), hypercholesterolaemia (P < 0.001) and
hyperuricaemia (P < 0.001). While arginase inhibition by
citrulline, norvaline or ornithine completely prevented the
developed hypertriglyceridaemia (all at P < 0.001), it did not
significantly affect the developed hypercholesterolaemia or
hyperuricaemia (Table 1). In addition, there were strong sta-
tistically significant correlations between arginase activity (as
shown in Figure 1) and each of the following: insulin resist-
ance index (r = 0.71, P < 0.01) and triglycerides (r = 0.81, P <
0.001) in all experimental groups.
Blood pressure
Fructose administration was associated with significant eleva-
tions in systolic and diastolic BP (both at P < 0.001, Figure 2).
The elevation in systolic BP was significantly inhibited by
citrulline (P < 0.01), ornithine (P < 0.01) and norvaline (P <
0.001) treatment while the elevated diastolic BP was signifi-
Figure 1
Effect of fructose-induced metabolic syndrome (M, 10% in drinking
water, for 12 weeks) and daily oral administration (last 6 weeks)
of citrulline (50 mg·kg-1), norvaline (50 mg·kg-1) or ornithine
(200 mg·kg-1) on serum arginase activity (A) or the effect of in vitro
incubation with uric acid (400 mM, 1 h), citrulline (1 mM, 1 h) or
arginine (1 mM, 1 h) on aortic arginase activity (B). *P < 0.05, **P <
0.01, ***P < 0.001, compared with the corresponding control group
values; #P < 0.05, ##P < 0.01, ###P < 0.001 compared with the
corresponding M group values; by one-way ANOVA and Newman–
Keuls post hoc test.
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cantly inhibited by all the arginase inhibitors used (all at P <
0.001, Figure 2). In addition, diastolic BP significantly corre-
lated with arginase activity (r = 0.66, P < 0.001).
Vascular reactivity
Cumulative addition of PE (10-9 to 10-5 M) or KCl (10-2 to
10-1 M) to the organ bath resulted in concentration-
dependent contractions of aorta in all the groups (Figure 3).
Metabolic syndrome induced by fructose (10% in drinking
water for 12 weeks) resulted in a large increase in aorta
responsiveness to PE, reflected by a significant increase in
apparent Emax (P < 0.001, Figure 3A, Table 2). In vivo treatment
of animals with the arginase inhibitors citrulline, ornithine
or norvaline had no significant effect on the response of
isolated aorta to PE (Figure 3A, Table 2). Metabolic syndrome
was associated with an increase in the aortic responsiveness
to KCl as shown by a significant increase in the apparent Emax
(P < 0.001, Figure 3B, Table 2). Similarly, in vivo arginase inhi-
bition by citrulline, ornithine or norvaline did not signifi-
cantly affect the response of isolated aorta to KCl (Figure 3B,
Table 2). Cumulative addition of ACh (10-9 to 10-5 M) to the
organ bath resulted in concentration-related decreases in
the tension of aortic artery rings pre-contracted with PE
(Figure 3C, Table 2). Metabolic syndrome was associated with
a large decrease in aorta responsiveness to ACh, reflected by a
significant decrease in apparent Emax (P < 0.01) compared with
the control (Figure 3C, Table 2). However, this impairment in
isolated aorta response to ACh was prevented by in vivo treat-
ment with citrulline, ornithine or norvaline (all at P < 0.001,
Figure 3C, Table 2).
Incubation of isolated aorta from metabolic syndrome
animals with any of the arginase inhibitors (citrulline, nor-
valine or ornithine, all at 1 mM for 1 h) did not affect the
aortic hyperresponsiveness to PE (Figure 4A, Table 3). Simi-
larly, none of the arginase inhibitors used affected the meta-
bolic syndrome-induced aortic hyperresponsiveness to KCl
(Figure 4B). In contrast, the impairment in response to ACh
in aorta isolated from animals with metabolic syndrome (P <
0.01, Figure 4C, Table 3) was corrected by arginase inhibition
with citrulline (P < 0.05) or ornithine (P < 0.05, Figure 4C,
Table 3).
Table 1
Effect of fructose-induced metabolic syndrome (M, 10% in drinking water, for 12 weeks) and daily oral administration (last 6 weeks) of citrulline
(50 mg·kg-1), norvaline (50 mg·kg-1) or ornithine (200 mg·kg-1) on serum levels of glucose and insulin, insulin resistance (IR) index, triglycerides,
total cholesterol and uric acid
Treatment
Glucose
(mg·ml-1)
Insulin
(mg·l-1) IR index
Triglycerides
(mg·ml-1)
Total cholesterol
(mg·ml-1)
Uric acid
(mM)
Control 6.1  0.6 3.4  0.4 0.5  0.1 9.4  0.8 5.7  0.7 0.4  0.03
M 12.0  0.7*** 13.0  0.9*** 3.9  0.6*** 16.5  2.3*** 13.8  1.0*** 3.2  0.1***
M-Citrulline 6.9  0.6### 5.2  0.6### 0.9  0.1### 7.6  0.5### 13.6  0.9 3.1  0.2
M-Ornithine 6.8  1.1### 5.4  1.1### 1.0  0.3### 4.7  0.4### 13.3  1.7 2.3  0.2
M-Norvaline 8.8  0.4## 5.6  1.3### 1.2  0.2### 7.7  0.8### 11.9  1.0 2.8  0.2
Values are expressed as the mean  SE of mean; n = 8 animals; *P < 0.05, **P < 0.01, ***P < 0.001, compared with the corresponding control
group values; #P < 0.05, ##P < 0.01, ###P < 0.001 compared with the corresponding metabolic syndrome group values; by one-way ANOVA and
Newman–Keuls post hoc test.
Figure 2
Effect of fructose- induced metabolic syndrome (M, 10% in drinking
water, for 12 weeks) and daily oral administration (last 6 weeks)
of citrulline (50 mg·kg-1), norvaline (50 mg·kg-1) or ornithine
(200 mg·kg-1) on the systolic (A) and diastolic (B) blood pressure. *P
< 0.05, **P < 0.01, ***P < 0.001, compared with the corresponding
control group values; #P < 0.05, ##P < 0.01, ###P < 0.001 compared
with the corresponding M group values; by one-way ANOVA and
Newman–Keuls post hoc test.
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In experiments designed to assess the effect of uric acid on
tissue responsiveness, incubation of isolated aorta from a
normal animal for 1 h with uric acid (200 mM) had no sig-
nificant effect on the aortic response to PE (Figure 5A,
Table 4) or to KCl (Figure 5B, Table 4) compared to control.
However, it significantly impaired the relaxation response to
ACh (P < 0.001, Figure 5C, Table 4) compared to control. This
impaired response to ACh due to incubation with uric acid
was significantly prevented by co-incubation with any of the
arginase inhibitors used (citrulline, ornithine and norvaline
all at 1 mM and P < 0.05, Figure 5C, Table 4).
Microvascular reactivity
Cumulative injection of ACh, in doses of 0.1 to 500 nmol,
resulted in dose-related decreases in the perfusion pressure of
isolated kidney pre-contracted with PE (Figure 5D). Perfusion
Figure 3
Effect of fructose- induced metabolic syndrome (M, 10% in drinking
water, for 12 weeks) and daily oral administration (last 6 weeks)
of citrulline (50 mg·kg-1), norvaline (50 mg·kg-1) or ornithine
(200 mg·kg-1) on the isolated aorta responsiveness to PE (A), KCl (B)
and ACh (C). Symbols indicate mean  SEM for n = 6–8 animals;
*P < 0.05, **P < 0.01, ***P < 0.001, compared with the correspond-
ing control group values; #P < 0.05, ##P < 0.01, ###P < 0.001 com-
pared with the corresponding M group values; by one-way ANOVA
and Newman–Keuls post hoc test.
Figure 4
Effect of in vitro incubation with citrulline (1 mM, 1 h), norvaline
(1 mM, 1 h) or ornithine (1 mM, 1 h) on the isolated metabolic
syndrome (M) aorta responsiveness to PE (A), KCl (B) and ACh (C).
Symbols indicate mean  SEM for n = 6–8 animals; *P < 0.05, **P <
0.01, ***P < 0.001, compared with the corresponding control group
values; #P < 0.05, ##P < 0.01, ###P < 0.001 compared with the
corresponding M group values; by one-way ANOVA and Newman–
Keuls post hoc test.
BJP HM El-Bassossy et al.
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Table 2
Effect of fructose-induced metabolic syndrome (M, 10% in drinking water, for 12 weeks) and daily oral administration (last 6 weeks) of citrulline
(50 mg·kg-1), norvaline (50 mg·kg-1) or ornithine (200 mg·kg-1) on the maximal response (Emax) and pD2 (-Log EC50) or EC50 values of PE, KCl and
ACh dose response curves
Treatment
KCl PE ACh
Emax EC50 Emax pD2 Emax pD2
Control 401.8  29.0 8.3  13.7 598.2  25.8 6.7  0.1 94.3  2.6 7.5  0.1
M 882.7  32.4*** 19.4  3.7 1091.0  53.0*** 7.0  0.1 61.3  4.1*** 7.4  0.2
M-Citrulline 757.1  45.1 17.4  10.1 933.9  46.7 6.8  0.1 81.2  3.2### 7.6  0.1
M-Ornithine 779.2  33.3 16.7  5.4 1063.0  54.7 7.1  0.2 86.3  2.7### 7.4  0.1
M-Norvaline 777.5  25.4 20.6  3.1 925.9  38.4 7.1  0.1 89.5  3.9### 8.0  0.1##
Values are expressed as the mean  SE of mean; n = 6–8 animals; *P < 0.05, **P < 0.01, ***P < 0.001, compared with the corresponding
control group values; #P < 0.05,##P < 0.01, ###P < 0.001 compared with the corresponding MS group values; by one-way ANOVA and
Newman–Keuls post hoc test.
Table 3
Effect of in vitro incubation with cirulline (1 mM, 1 h), norvaline (1 mM, 1 h) or ornithine (1 mM, 1 h) on the maximal response (Emax) and pD2
(-Log EC50) or EC50 values of PE, KCl and ACh dose response curves of the isolated metabolic syndrome (M) aorta
Treatment
KCl PE ACh
Emax EC50 Emax pD2 Emax pD2
Control 437.2  29.4 8.3  11.0 567.4  37.3 6.8  0.1 95.8  3.9 7.7  0.1
M 920.6  32.0*** 19.1  3.4 1225.0  70.9*** 7.0  0.1 66.5  4.1** 7.4  0.1
M + Citrulline 818.1  31.4 17.6  4.2 1016.0  97.9 7.0  0.2 88.4  6.2# 7.7  0.2
M + Ornithine 868.0  39.4 21.5  4.1 1014.0  60.7 7.0  0.1 89.1  6.3# 7.8  0.2
M + Norvaline 877.0  25.8 21.1  2.9 1142.0  58.7 7.0  0.1 83.1  3.9 8.1  0.1
Values are expressed as the mean  SE of mean; n = 6–8 animals; *P < 0.05, **P < 0.01, ***P < 0.001, compared with the corresponding
control group values; #P < 0.05,##P < 0.01, ###P < 0.001 compared with the corresponding MS group values; by One Way ANOVA and Newman
Keuls post hoc test.
Table 4
Effect of in vitro incubation with uric acid (400 mM, 1 h) with or without cirulline (1 mM, 1 h), norvaline (1 mM, 1 h) or ornithine (1 mM, 1 h)
on the maximal response (Emax) and pD2 (-Log EC50) or EC50 values of PE, KCl and ACh dose response curves of the isolated normal aorta
Treatment
KCl PE ACh
Emax EC50 Emax pD2 Emax pD2
Control 437.2  29.4 15.5  5.5 609.3  36.4 -6.8  0.1 95.3  2.2 7.4  0.1
Uric acid 534.2  19.3 15.4  5.8 879.8  66.4** -7.2  0.2 38.9  5.4*** 6.7  0.2*
Uric acid + citrulline 478.6  46.6 -2.2  65.3 915.4  72.1 -7.6  0.3 76.9  5.7### 6.9  0.1
Uric acid + ornithine 484.3  30.0 17.9  10.4 920.1  65.5 -7.3  0.2 74.9  8.5### 6.9  0.2
Uric acid + norvaline 490.3  33.7 19.2  5.9 962.8  79.3 -7.7  0.4 78.8  5.3### 7.1  0.1
Values are expressed as the mean  SE of mean; n = 6–8 animals; *P < 0.05, **P < 0.01, ***P < 0.001, compared with the corresponding
control group values; #P < 0.05,##P < 0.01, ###P < 0.001 compared with the corresponding uric acid group values; by one-way ANOVA and
Newman–Keuls post hoc test.
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of isolated normal kidney with buffer containing uric acid
(200 mM) for 1 h led to a significant reduction in the reno-
vascular relaxation response to ACh (P < 0.001, Figure 5D).
This impaired response to ACh due to incubation with uric
acid was significantly inhibited by 30 min perfusion with
buffer containing 1 mM citrulline (P < 0.01, Figure 5D).
ACh-induced NO generation
Addition of ACh (10-4M) to DAF-loaded aorta from normal
animals induced a strong increase in NO production, as
assessed by increased fluorescence. However, metabolic syn-
drome significantly inhibited the Ach-stimulated NO release
compared to control animals, reflected by a significantly
reduced apparent Emax (P < 0.001, Figure 6A). Interestingly,
this impaired aortic NO generation was completely prevented
by arginase inhibition by citrulline (P < 0.001), ornithine (P <
0.05) or norvaline (P < 0.01, 6A).
Intracellular ROS generation
Aorta isolated from animals with metabolic syndrome had a
significantly increased ROS generation (P < 0.001, Figure 6B)
compared to control. Interestingly all the arginase inhibitors
(citrulline, norvaline and ornithine) significantly decreased
ROS generation (all at P < 0.001, Figure 6B). Moreover, we
found strong correlations between ROS generation and argi-
nase activity (r = 0.75, P < 0.001) and between the ROS
generation and the insulin level (r = 0.67, P < 0.01).
Control experiments
None of the used arginase inhibitors citrulline, norvaline or
ornithine affected the previously mentioned parameters com-
pared to control when given to normal animals for the same
periods of time (data not shown).
Discussion and conclusions
The current study is the first to report on the potential pro-
tective effect of arginase inhibition against the hypertension
associated with metabolic syndrome. The arginase inhibitors
citrulline, ornithine or norvaline virtually inhibited the
development of hypertension in fructose-induced metabolic
syndrome in rats. The following findings can explain the
ability of arginase inhibition to counteract hypertension
accompanying metabolic syndrome: (i) arginase inhibition
ameliorated the impaired ACh-induced relaxations associated
with metabolic syndrome; (ii) the impaired NO and increased
ROS generation in metabolic syndrome were abrogated by
arginase inhibition; and (iii) arginase inhibition prevented
the development of insulin resistance and hypertriglyceridae-
Figure 5
Effect of in vitro incubation with uric acid (200 mM, 1 h) with or without cirulline (1 mM, 1 h), norvaline (1 mM, 1 h) or ornithine (1 mM, 1 h)
on the isolated normal aorta responsiveness to PE (A), KCl (B) and ACh (C) or on the isolated perfused kidney relaxation to ACh (D). Symbols
indicate mean  SEM for n = 6–8 animals; *P < 0.05, **P < 0.01, ***P < 0.001, compared with the corresponding control group values; #P < 0.05,
##P < 0.01, ###P < 0.001 compared with the corresponding uric acid values; by one-way ANOVA and Newman–Keuls post hoc test.
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mia in metabolic syndrome. These findings provide con-
vincing evidence that arginase offsets the hypertension
accompanying the metabolic syndrome through endothelial-
dependent relaxation NO signalling protection.
We reasoned that arginase inhibition would mitigate or at
least minimize the hypertension components of the meta-
bolic syndrome. The validity of this assumption was ascer-
tained in this work because all the arginase inhibitors used
significantly inhibited the elevations in diastolic and systolic
BP seen in animals with metabolic syndrome. The elevated
systolic (after load) BP in diabetic animals could be due to
cardiac complication and/or aortic stiffness while the
elevated diastolic (pre-load) BP is attributed to the impaired
vascular reactivity observed in diabetic animals. Aortic stiff-
ness has been reported to be responsible for augmented pres-
sure in late systole (O’Rourke and Nichols, 2005).
We focused on the impairment in vascular reactivity
because of its importance in the development of hyperten-
sion (Mansour et al., 2011) and in metabolic syndrome-
evoked hypertension in particular (Schinzari et al., 2010).
The findings of the present study highlight a pivotal role
for vascular reactivity in the amelioration of metabolic
syndrome-evoked hypertension by arginase inhibition. We
have found increased contraction of isolated aorta to PE and
KCl and decreased relaxation to ACh in animals with meta-
bolic syndrome, while arginase inhibitors prevented the
impaired relaxation to ACh in aorta isolated from animals
with metabolic syndrome without affecting the response to
PE or KCl. These findings are supported by previous reports
from us and other laboratories, which showed increased
response to different vasoconstrictors (El-Bassossy et al.,
2011a; Mahmoud et al., 2012) and impaired endothelium-
dependent dilatation (Verma et al., 1996; Takagawa et al.,
2001) due to insulin resistance. In addition, we have previ-
ously shown that arginase inhibition alleviates hypertension
and impaired endothelial-dependent relaxation associated
with insulin deficiency (El-Bassossy et al., 2012b).
We used three inhibitors that are known to inhibit argi-
nase enzyme by different ways in order to confirm that the
observed protection is most likely due to arginase enzyme
inhibition and not due to a direct effect of the inhibitors.
Ornithine inhibits arginase enzyme by competing with its
substrate L-arginine on the active sites of the enzyme. Nor-
valine is a non-competitive inhibitor of the arginase enzyme
(Hunter and Downs, 1945). L-citrulline is an allosteric inhibi-
tor of arginase (Shearer et al., 1997).
In the present work, we found increased arginase activity
in animals with metabolic syndrome while all the inhibitors
showed a significant inhibition of arginase activity at the
doses and durations used. The protective effect of arginase
inhibition on elevated diastolic BP in animals with metabolic
syndrome seems to be through direct and indirect mecha-
nisms. The direct protective effect is via improving relaxa-
tion. This is because acute in vitro arginase inhibition
significantly increased endothelial-dependent relaxation in
aorta isolated from animals with metabolic syndrome in this
study. The indirect protective effect of arginase inhibition is
through amelioration of the developed insulin resistance. In
the present work, arginase inhibition was statistically corre-
lated with the reduction in the developed insulin resistance.
This points to the role of arginase enzyme activity in the
metabolic syndrome. Hyperuricaemia is one of the important
components of the metabolic syndrome and is a true risk
factor for cardiovascular disease in metabolic syndrome. The
proposed mechanism is through inhibiting endothelial-
dependent relaxation and NO production (Heinig and
Johnson, 2006). In this study, in vitro incubation with
uric acid at the concentration seen in animals with meta-
bolic syndrome significantly impairs endothelial-dependent
relaxation in aorta isolated from normal animals. To test if
the observed hyperuricaemia is responsible for arginase acti-
vation in metabolic syndrome, we found that in vitro incuba-
tion with uric acid did not significantly affect the arginase
activity in isolated vessels. On the other hand, the observed
uric acid-induced impairment in relaxation was prevented by
co-incubation with any of the arginase inhibitors while none
of them affected the serum level of uric acid in animals with
metabolic syndrome. This suggests an indirect relationship
between hyperuricaemia and arginase enzyme in metabolic
syndrome.
Figure 6
Effect of fructose- induced metabolic syndrome (M, 10% in drinking
water, for 12 weeks) and chronic daily oral administration (last 6
weeks) of citrulline (50 mg·kg-1), norvaline (50 mg·kg-1) or ornithine
(200 mg·kg-1) on ACh-stimulated NO generation (A) and basal ROS
formation (B). Symbols indicate mean  SEM for n = 6–8 animals; *P
< 0.05, **P < 0.01, ***P < 0.001, compared with the corresponding
control group values; #P < 0.05, ##P < 0.01, ###P < 0.001 compared
with the corresponding M group values; by one-way ANOVA and
Newman–Keuls post hoc test.
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The mechanism(s) by which arginase inhibition protects
against the impairment in endothelium-dependent relaxa-
tion could be mediated, at least in part, by modulation of
NO production. In this work, treatment with any of the
arginase inhibitors prevented the impairment in Ach-
stimulated NO generation in aorta isolated from animals
with metabolic syndrome. Reducing arginase activity via
dietary manganese deficiency has been previously reported
to enhance endothelium-dependent vasorelaxation of rat
aorta (Ensunsa et al., 2004). The observed protection of
ACh-stimulated NO generation due to arginase inhibition in
metabolic syndrome could be due to inhibition of eNOS
uncoupling and NO quenching by ROS. Arginase inhibition
restores the availability of L-arginine for eNOS and limits
NO inactivation by superoxide anion produced by eNOS as
a result of arginine depletion (Santhanam et al., 2008). In
support of this, we have found a significant reduction in
ROS generation in vessels isolated from animals with meta-
bolic syndrome due to arginase inhibition. The decrease in
ROS generation seems to be due to inhibition of eNOS
uncoupling that follow arginase inhibition in this study.
Modulation of eNOS co-factors like BH4 is another possibil-
ity of restored ACh-induced NO generation by arginase
inhibition in metabolic syndrome as BH4 can be easily oxi-
dized by ROS. In a previous report from our group, we
found that external addition of BH4 blocks the attenua-
tion in ACh-stimulated NO generation (El-Bassossy et al.,
2009).
The possibility that alterations in circulating lipid profile
contributed to the metabolic syndrome–arginase hemody-
namic interaction was also investigated. Dyslipidemia is asso-
ciated with increased cardiovascular morbidity and mortality
(Robins et al., 2003). Our findings showed that the metabolic
syndrome was characterized by hypertriglyceridaemia and
hypercholesterolaemia. While arginase inhibition did not
affect the developed hypercholesterolaemia, it completely
prevented hypertriglyceridaemia associated with metabolic
syndrome. In addition, serum triglyceride levels were
strongly correlated with arginase activity in all groups. These
observations strongly suggest a role of arginase enzyme in the
hypertriglyceridaemia associated with metabolic syndrome. A
possible explanation to this novel finding is that increased
arginase activity limits L-arginine for eNOS and hence
reduces NO production. NO plays an important role in reduc-
ing triglycerides level. It was found that diets rich in nitrite
promote NO production and reduce triglycerides in humans
(Zand et al., 2011), while the NO synthase inhibitor
L-N{omega}nitroarginine (L-NNA) elevates serum triglyceride
(Goto et al., 1999). The effect of NO on serum triglyceride
levels might be due to reduced fatty acid oxidation as it has
been shown that inhibiting NO synthase by L-NNA lowered
the activity of hepatic carnitine palmitoyl transferase, the
rate-limiting enzyme of fatty acid oxidation (Goto et al.,
1999).
In conclusion, arginase inhibition by citrulline, norva-
line or ornithine alleviates hypertension associated with
metabolic syndrome by direct and indirect protective
mechanisms. The direct protective mechanism is through
maintenance of endothelial-dependent relaxation and NO
generation, while the indirect mechanism is through inhibi-
tion of insulin resistance and hypertriglyceridaemia.
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